Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
Faye Horner,* Peck Lin Lip,* Bushra Mushtaq, Randhir Chavan, Bashar Mohammed, Arijit Mitra Birmingham and Midland Eye Centre, Sandwell & West Birmingham NHS Trust, Birmingham B18 7QH, UK*These authors contributed equally to this workCorrespondence: Peck Lin LipBirmingham and Midland Eye Cent...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b42b245adad0412a9d4e291fbfa5469a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b42b245adad0412a9d4e291fbfa5469a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b42b245adad0412a9d4e291fbfa5469a2021-12-02T09:19:59ZCombination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice1177-5483https://doaj.org/article/b42b245adad0412a9d4e291fbfa5469a2020-03-01T00:00:00Zhttps://www.dovepress.com/combination-therapy-for-macular-oedema-in-retinal-vein-occlusions-3-ye-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Faye Horner,* Peck Lin Lip,* Bushra Mushtaq, Randhir Chavan, Bashar Mohammed, Arijit Mitra Birmingham and Midland Eye Centre, Sandwell & West Birmingham NHS Trust, Birmingham B18 7QH, UK*These authors contributed equally to this workCorrespondence: Peck Lin LipBirmingham and Midland Eye Centre, Sandwell & West Birmingham NHS Trust, City Hospital Dudley Road, Birmingham B18 7QH, UKTel +44 121 5543801Fax +44 121 5076791Email pllipwoo@gmail.comPurpose: To report long-term efficacy and treatment outcomes of the combination therapy for treating macular oedema (MO) in retinal vein occlusions (RVOs) from a real-world UK practice.Methods: The initial reported 66 RVO patients with MO treated with combination therapy (initial Ranibizumab, later optional addition of Ozurdex and laser) were followed up to Year 3: visual acuity (VA) and central retinal thickness (CRT) were analysed against baseline and previous Year 1 results. Safety and adverse events were also recorded.Results: Baseline LogMAR VA of 0.71 (Snellen 6/30) improved to 0.48 (Snellen 6/18) at Year 3 (p= 0.006); 63% experienced VA improvement (40% improved ≥ 3 lines), 27% had worse vision. Stability of mean VA (6/18) was already achieved at first post-loading phase review and was maintained in each subsequent year. Statistically significant CRT improvement was noted in each year (Year 3 median CRT=264μm) compared to baseline (median CRT=531μm). There was a reduction in the mean number of total injections to 2.5 in Year 3 (vs 5.5 in Year 1). Comparing Year 3 against Year 1, mean Ranibizumab injection frequency was 2.1 vs 4.3; mean Ozurdex injection frequency was 0.2 vs 1.1. In Year 3, 39.6% of patients did not require any form of injections, laser frequency was also reduced to 22.9% (vs 81.8% in Year 1). There was no endophthalmitis in the cohort, one progressed to neovascular glaucoma in Year 2 and mortality rate was recorded as 6%.Conclusion: Our real-world clinical practice for RVO patients using a combined therapy is associated with good long-term VA and anatomical outcomes with less intravitreal re-treatment rates.Keywords: RandOL protocol, Ozurdex, ischaemia, laser, mortality, aspirin Horner FLip PLMushtaq BChavan RMohammed BMitra ADove Medical Pressarticlerandol protocolozurdexischaemialasermortalityaspirin.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 955-965 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
randol protocol ozurdex ischaemia laser mortality aspirin. Ophthalmology RE1-994 |
| spellingShingle |
randol protocol ozurdex ischaemia laser mortality aspirin. Ophthalmology RE1-994 Horner F Lip PL Mushtaq B Chavan R Mohammed B Mitra A Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| description |
Faye Horner,* Peck Lin Lip,* Bushra Mushtaq, Randhir Chavan, Bashar Mohammed, Arijit Mitra Birmingham and Midland Eye Centre, Sandwell & West Birmingham NHS Trust, Birmingham B18 7QH, UK*These authors contributed equally to this workCorrespondence: Peck Lin LipBirmingham and Midland Eye Centre, Sandwell & West Birmingham NHS Trust, City Hospital Dudley Road, Birmingham B18 7QH, UKTel +44 121 5543801Fax +44 121 5076791Email pllipwoo@gmail.comPurpose: To report long-term efficacy and treatment outcomes of the combination therapy for treating macular oedema (MO) in retinal vein occlusions (RVOs) from a real-world UK practice.Methods: The initial reported 66 RVO patients with MO treated with combination therapy (initial Ranibizumab, later optional addition of Ozurdex and laser) were followed up to Year 3: visual acuity (VA) and central retinal thickness (CRT) were analysed against baseline and previous Year 1 results. Safety and adverse events were also recorded.Results: Baseline LogMAR VA of 0.71 (Snellen 6/30) improved to 0.48 (Snellen 6/18) at Year 3 (p= 0.006); 63% experienced VA improvement (40% improved ≥ 3 lines), 27% had worse vision. Stability of mean VA (6/18) was already achieved at first post-loading phase review and was maintained in each subsequent year. Statistically significant CRT improvement was noted in each year (Year 3 median CRT=264μm) compared to baseline (median CRT=531μm). There was a reduction in the mean number of total injections to 2.5 in Year 3 (vs 5.5 in Year 1). Comparing Year 3 against Year 1, mean Ranibizumab injection frequency was 2.1 vs 4.3; mean Ozurdex injection frequency was 0.2 vs 1.1. In Year 3, 39.6% of patients did not require any form of injections, laser frequency was also reduced to 22.9% (vs 81.8% in Year 1). There was no endophthalmitis in the cohort, one progressed to neovascular glaucoma in Year 2 and mortality rate was recorded as 6%.Conclusion: Our real-world clinical practice for RVO patients using a combined therapy is associated with good long-term VA and anatomical outcomes with less intravitreal re-treatment rates.Keywords: RandOL protocol, Ozurdex, ischaemia, laser, mortality, aspirin
|
| format |
article |
| author |
Horner F Lip PL Mushtaq B Chavan R Mohammed B Mitra A |
| author_facet |
Horner F Lip PL Mushtaq B Chavan R Mohammed B Mitra A |
| author_sort |
Horner F |
| title |
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| title_short |
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| title_full |
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| title_fullStr |
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| title_full_unstemmed |
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice |
| title_sort |
combination therapy for macular oedema in retinal vein occlusions: 3-year results from a real-world clinical practice |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/b42b245adad0412a9d4e291fbfa5469a |
| work_keys_str_mv |
AT hornerf combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice AT lippl combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice AT mushtaqb combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice AT chavanr combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice AT mohammedb combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice AT mitraa combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice |
| _version_ |
1718398142745935872 |